<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
		>
<channel>
	<title>Comments on: Clouds Over the VC sky</title>
	<atom:link href="http://bostonbiotechwatch.com/2009/10/26/clouds-over-the-vc-sky/feed/" rel="self" type="application/rss+xml" />
	<link>http://bostonbiotechwatch.com/2009/10/26/clouds-over-the-vc-sky/</link>
	<description>Just another WordPress.com weblog</description>
	<lastBuildDate>Wed, 10 Feb 2010 13:01:15 +0000</lastBuildDate>
	<generator>http://wordpress.com/</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Domain Sheds the VC Blues &#171; Boston Biotech Watch</title>
		<link>http://bostonbiotechwatch.com/2009/10/26/clouds-over-the-vc-sky/#comment-51</link>
		<dc:creator>Domain Sheds the VC Blues &#171; Boston Biotech Watch</dc:creator>
		<pubDate>Wed, 10 Feb 2010 13:01:15 +0000</pubDate>
		<guid isPermaLink="false">http://bostonbiotechwatch.com/?p=31#comment-51</guid>
		<description>[...] Worse for VCs, fund-raising is down and the returns for many if not most funds have been negative for years. The actual numbers are unknown, though Boston Biotech Watch’s parent CBT Advisors got access to some aggregate data in 2008 that was pretty sobering, showing a majority of 232 healthcare funds over twenty-two years returning barely more than their invested capital, data we will share upon request. The reasons for this fund-raising roadblock have much to do with that performance, intensified by the structural issues that have beset many of the funds’ limited partners, an issue Boston Biotech Watch covered in an earlier post. [...]</description>
		<content:encoded><![CDATA[<p>[...] Worse for VCs, fund-raising is down and the returns for many if not most funds have been negative for years. The actual numbers are unknown, though Boston Biotech Watch’s parent CBT Advisors got access to some aggregate data in 2008 that was pretty sobering, showing a majority of 232 healthcare funds over twenty-two years returning barely more than their invested capital, data we will share upon request. The reasons for this fund-raising roadblock have much to do with that performance, intensified by the structural issues that have beset many of the funds’ limited partners, an issue Boston Biotech Watch covered in an earlier post. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
